miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma
Open Access
- 16 April 2020
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (2), 610-613
- https://doi.org/10.3324/haematol.2019.241307
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanismLeukemia, 2015
- Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK–positive anaplastic large-cell lymphomaBlood, 2014
- PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomasNature Medicine, 2012
- Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosisLeukemia, 2012
- Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)–Type First-Line Therapy: A BFM-Group StudyJournal of Clinical Oncology, 2011
- NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma2011
- The anaplastic lymphoma kinase in the pathogenesis of cancerNature Reviews Cancer, 2008
- The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signalingBlood, 2007
- The Expression of CD30 in Anaplastic Large Cell Lymphoma Is Regulated by Nucleophosmin-Anaplastic Lymphoma Kinase–Mediated JunB Level in a Cell Type–Specific MannerCancer Research, 2006
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's LymphomaScience, 1994